Taigexyn (nemonoxacin) / TaiGen, R-Pharm - LARVOL DELTA

Isolated IgG4-related lung disease: a case report. (PubMed, AME Case Rep) - "Chest computed tomography (CT) initially showed right upper lobe lesions suggestive of pneumonia, but the patient failed to respond to multiple courses of antibiotics including levofloxacin, nemonoxacin malate, ceftizoxime, and amoxicillin...The patient was treated with oral cyclosporine and mycophenolate mofetil, resulting in significant clinical and radiological improvement...Comprehensive evaluation including serum IgG4 measurement and targeted pathological biopsy is essential for accurate diagnosis. Early initiation of immunosuppressive therapy can effectively improve outcomes and prevent disease progression."

Journal • Cough • Infectious Disease • Inflammation • Interstitial Lung Disease • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases

Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review. (PubMed, Antibiotics (Basel)) - "Given the limited number of antibiotics for treating CDI and fidaxomicin nonavailability in many countries, it is necessary to conduct more extensive laboratory and clinical studies of promising antibiotics such as ibezapolstat, delafloxacin, lascufloxacin, omadacycline, eravacycline, ridinilazole, and CRS3123...Research on rifasutenizol for bacterial vaginosis, sarecycline and nadifloxacin for acne vulgaris and amixicile for periodontal diseases needs to be expanded. For H. pylori infection, delafloxacin, sitafloxacin, nemonoxacin, zoliflodacin, and rifasutenizol may improve the suboptimal success of most eradication regimens...Establishing more research groups, careful examination of market issues, and additional approaches, such as nanomaterials, efflux pump inhibitors, phage therapy, and CRISPR-Cas systems, should be beneficial. Notwithstanding the difficulties, there are many opportunities to promote research on and potential use of newer antibiotics which show..."

Journal • Review • Acne Vulgaris • Dental Disorders • Dermatology • Infectious Disease • Periodontitis • Vaginitis

Nemonoxacin pharmacokinetics/pharmacodynamics against Escherichia coli in an in vitro dynamic urinary tract infection model. (PubMed, Antimicrob Agents Chemother) - "The 500 mg regimen achieved ≥90% PTA for isolates with MIC ≤ 16 mg/L (CFR 92.1%) using CAMHB-derived targets but only ≤8 mg/L (CFR 59.4%) in SHU. A 500 mg once-daily regimen of nemonoxacin appears to be a promising therapeutic option for the treatment of uUTIs, although further clinical studies are necessary to validate these findings."

Journal • PK/PD data • Preclinical • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

A case of severe Legionella pneumonia treated with omadacycline and nemonoxacin. (PubMed, Respir Med Case Rep) - "We report a 59-year-old man with severe community-acquired pneumonia(sCAP) who initially received empiric ceftazidime-avibactam plus nemonoxacin. The combination led to rapid improvements in inflammatory markers, hypoxemia, and creatine kinase levels. This case provides a clinical rationale for using omadacycline plus nemonoxacin as salvage therapy in severe Legionella pneumonia when conventional regimens fail."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia. (PubMed, Front Pharmacol) - "Sensitivity analysis supported the robustness of the economic finding. Nemonoxacin malate injection demonstrates clinical efficacy and safety comparable to moxifloxacin hydrochloride injection for CAP, while incurring significantly lower treatment costs, resulting in a more favorable economic profile."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases

The latest research progress on the clinical application of nemonoxacin. (PubMed, Front Med (Lausanne)) - "Its unique pharmacological properties confer high clinical application value. In the context of bacterial resistance, this article aims to provide a comprehensive review of nemonoxacin's antibacterial activity, immunomodulatory effects, and its application in infectious diseases as well as in patients with hepatic or renal insufficiency, with the goal of offering more drug options for clinical treatment and providing a reference for future clinical research and widespread application."

Journal • Review • Infectious Disease • Liver Failure • Nephrology • Renal Disease

Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones. (PubMed, J Antimicrob Chemother) - "Nocardia spp. exhibited varying patterns of susceptibility to carbapenems and fluoroquinolones respectively. Importantly, different Nocardia spp. exhibited different patterns of susceptibility to carbapenems and fluoroquinolones, respectively."

Journal

Top 20 Research Studies of 2024 for Primary Care Physicians. (PubMed, Am Fam Physician) - "Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus...Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome...Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss...For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates...Oral naltrexone and acamprosate are safe and effective treatments for alcohol use..."

Journal • Review • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Diabetes • Fatigue • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Novel Coronavirus Disease • Obesity • Otorhinolaryngology • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • Sinusitis • Type 2 Diabetes Mellitus

Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study (clinicaltrials.gov) - P=N/A | N=144 | Active, not recruiting | Sponsor: National Taiwan University Hospital

New trial • Infectious Disease

In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study. (PubMed, BMC Microbiol) - "S. pneumoniae in China exhibits high genetic diversity and significant antibiotic resistance, underscoring the need for continuous surveillance and updated vaccines. New antibiotics remain effective against multidrug-resistant strains, offering potential treatment options in clinical settings."

Clinical • Journal • Preclinical • Infectious Disease • Pneumococcal Infections • Pneumonia

Clinical utility of oral Nemonoxacin 500 mg once daily for the treatment of acute lower urinary tract infections: a prospective open-label, multicenter study. (PubMed, BMC Infect Dis) - P=N/A | "Nemonoxacin capsules 500 mg once daily is effective, safe, and well-tolerated for treatment of mild-to-moderate acute lower UTIs in adult outpatients."

Clinical • Journal • Dermatology • Infectious Disease • Nephrology • Pain • Pruritus

Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data (ESCMID Global 2025) - No abstract available

Clinical data • PK/PD data • Preclinical

Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan. (PubMed, Ann Clin Microbiol Antimicrob) - "Our study confirmed ST8/USA300 MRSA has disseminated in Taiwan. Using a tCBP defined by a higher parenteral daily dosage, nemonoxacin retained potency against moxifloxacin non-susceptible isolates. Patterns of AAS in QRDRs among different lineages may contribute to difference of nemonoxacin susceptibility."

Clinical • Journal • Preclinical • Infectious Disease

Determination of Nemonoxacin in Small Volumes of Rat Plasma and Bile by a Novel HPLC-Fluorescence Assay and Its Application to Disposition and Biliary Excretion Kinetics. (PubMed, Drug Des Devel Ther) - "A validated method was developed and found to be specific, precise and accurate. The applicability of this proposed method was substantiated in pharmacokinetic studies in rats."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Potential effectiveness of parenteral nemonoxacin in the treatment of Clostridioides difficile infections: in vitro, ex vivo, and mouse studies. (PubMed, Front Microbiol) - "However, the standard agent for treating CDIs is limited to oral fidaxomicin or vancomycin...For clinical isolates and laboratory strains, lower MICs of nemonoxacin against C. difficile than levofloxacin and ciprofloxacin were observed, even in those harboring point mutations in the quinolone-resistance determining region...Similarly, no significant differences were found between mice receiving combination therapy of intraperitoneal nemonoxacin plus oral vancomycin and those treated with intraperitoneal nemonoxacin or oral vancomycin alone. The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models."

Journal • Preclinical • Infectious Disease

A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate versus levofloxacin for community-acquired pneumonia in adult patients. (PubMed, Int J Antimicrob Agents) - P3 | "Nemonoxacin 500 mg IV once daily for 7-14 days is effective and safe and noninferior to levofloxacin for treating CAP in adult patients."

Clinical • Journal • P3 data • Infectious Disease • Pneumonia • Respiratory Diseases

Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses. (PubMed, Clin Pharmacokinet) - "Several factors may influence interactions, including the physicochemical characteristics of quinolones, the type of intervention, drug formulation, and the patient's health status. We assessed the quality of evidence as low due to the poor actuality of included studies, their methodological diversity, and uneven data availability for individual drugs."

Review

Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis. (PubMed, J Gen Intern Med) - "We observed trends toward a better clinical response and lower mortality for quinolones as empiric antibiotics for CAP, but found no conclusive evidence of any antibiotic being clearly more effective than another. More trials are needed to inform guideline recommendations on the most effective antibiotic regimens for outpatients with mild to moderate CAP."

Retrospective data • Review • Infectious Disease • Pneumonia • Respiratory Diseases

Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: Unlocking ways to overcome resistance. (PubMed, Int J Biol Macromol) - "The fluoroquinolones like levofloxacin and moxifloxacin have been listed in class A drugs for treating MDR. Gatifloxacin and ciprofloxacin also proved its efficacy against MDR TB and MDR enteric fever in adults, whereas nemonoxacin can induce anti-MDR activity of other antibiotics already suggested by studies...In addition to fluoroquinolone, the natural compounds novobiocin and simocyclinone could also inhibit the gyrase, impressively which has been designed with the gyrase structure for better understanding. Herein, ongoing clinical development of some novel drugs possessing triazaacenaphthylenes, spiropyrimidinetriones, and oxazolidinone-quinolone hybrids have been highlighted which could further assist the future generation antibiotic development corroborating gyrase as a potential target against MDR pathogens."

Journal • Review

In vitro pharmacodynamics of nemonoxacin and other antimicrobial agents against Mycoplasma pneumoniae. (PubMed, Microbiol Spectr) - "The time-kill assays and pharmacodynamic analysis showed that nemonoxacin has significant mycoplasmacidal activity against MRMP and MSMP. This study paves the road to establish appropriate dosing protocols of a new antimicrobial drug for children infected with M. pneumoniae."

Journal • PK/PD data • Preclinical • Infectious Disease • Pneumonia

Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease. (PubMed, Sci Rep) - "Despite no significant difference in the incidence of exacerbations between two groups, patients treated with nemonoxacin had a significantly prolonged time to next moderate/severe exacerbation than those with moxifloxacin (p < 0.05). Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next moderate/severe exacerbation for AECOPD outpatients."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials. (PubMed, Cureus) - "Furthermore, the adverse effects associated with nemonoxacin are generally mild. Therefore, both the 500 mg and 750 mg dosages of nemonoxacin can be recommended as appropriate antibiotic therapy regimens for the treatment of CAP."

Clinical • Journal • Retrospective data • Review • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile? (PubMed, Pharmaceutics) - "The FDA and EMA approved delafloxacin. Additionally, lascufloxacin, levonadifloxacin, nemonoxacin, sitafloxacin, and zabofloxacin were approved in their origin countries...The main AEs of the FQs class were addressed, highlighting the existing data for the recently approved ones. In addition, the general management of AEs when they occur and the rational use and caution of modern FQs were outlined."

Adverse events • Journal • Review • Infectious Disease

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia. (PubMed, Front Pharmacol) - " Integrative PK/PD analysis justifies the reliable clinical and microbiological efficacy of nemonoxacin 500 mg q24 h in treating CAP caused by S. pneumoniae, S. aureus, and K. pneumoniae, irrespective of patient sex, mild renal impairment, empty stomach or not. However, nemonoxacin 750 mg q24 h would provide better efficacy than 500 mg q24 h for the CAP caused by H. parainfluenzae in terms of CFR."

Journal • PK/PD data • Infectious Disease • Influenza • Pneumococcal Infections • Pneumonia • Renal Disease • Respiratory Diseases

Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen Staphylococcus aureus Treated with Novel Bisphosphonate-Fluoroquinolone Antimicrobial Conjugates. (PubMed, Int J Mol Sci) - "We tested early and newer generation quinolone antibiotics (ciprofloxacin, moxifloxacin, sitafloxacin, and nemonoxacin) and several bisphosphonate-conjugated versions of these antibiotics (bisphosphonate-carbamate-sitafloxacin (BCS), bisphosphonate-carbamate-nemonoxacin (BCN), etidronate-carbamate-ciprofloxacin (ECC), and etidronate-carbamate-moxifloxacin (ECX)) and found that they were able to inhibit Staphylococcus aureus biofilms in a dose-dependent manner. They also retained the antimicrobial activity of the parent antibiotic in the presence or absence of hydroxyapatite, albeit at lower levels due to the nature of their chemical modification. These findings will aid in the optimization and testing of this novel class of drugs for future applications to pharmacotherapy in osteomyelitis."

Journal • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics